Literature DB >> 8413319

The mouse mammary tumor virus long terminal repeat encodes a 47 kDa glycoprotein with a short half-life in mammalian cells.

C Krummenacher1, H Diggelmann.   

Abstract

The mouse mammary tumor virus proviral DNA contains an open reading frame in the 3' long terminal repeat which can code for a 36 kDa polypeptide with a putative transmembrane sequence and five N-linked glycosylation sites. This gene is known to code for a superantigen which deletes a specific subset of CD4+ T lymphocytes in vivo. The superantigen encoded by the exogenous mouse mammary tumor virus of the GR strain acts specifically on V beta 14 bearing T cells. We produced recombinant vaccinia viruses to express either the complete or a truncated ORF protein after infection of primate cells in culture. The complete ORF gene in mammalian cells leads to the production of a 47 kDa protein which is specifically detected with an anti-ORF-peptide antiserum. The 47 kDa protein can be labeled with D-[2-3H]mannose and its synthesis is inhibited by tunicamycin, an N-linked glycosylation inhibitor, indicating that it is a glycoprotein. The truncated ORF protein beginning at the second ATG of the open reading frame is also modified, but the C-terminal half of ORF, starting at the fifth ATG, has the expected size of the non modified polypeptide. Pulse-chase experiments indicate that the ORF protein has a short half-life of about 1.5-2 hr.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8413319     DOI: 10.1016/0161-5890(93)90133-v

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  8 in total

1.  Alternative proteolytic processing of mouse mammary tumor virus superantigens.

Authors:  F Denis; N H Shoukry; M Delcourt; J Thibodeau; N Labrecque; H McGrath; J S Munzer; N G Seidah; R P Sékaly
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

2.  In vivo effects of a recombinant vaccinia virus expressing a mouse mammary tumor virus superantigen.

Authors:  C Krummenacher; H Diggelmann; H Acha-Orbea
Journal:  J Virol       Date:  1996-05       Impact factor: 5.103

3.  Identification of key amino acids of the mouse mammary tumor virus superantigen involved in the specific interaction with T-cell receptor V(beta) domains.

Authors:  F Baribaud; S Wirth; I Maillard; S Valsesia; H Acha-Orbea; H Diggelmann
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

4.  Negative-acting factor and superantigen are separable activities of the mouse mammary tumor virus long terminal repeat.

Authors:  S Wintersperger; B Salmons; T Miethke; V Erfle; H Wagner; W H Günzburg
Journal:  Proc Natl Acad Sci U S A       Date:  1995-03-28       Impact factor: 11.205

5.  Intercellular transfer of a soluble viral superantigen.

Authors:  M Reilly; D Mix; A A Reilly; X Y Ye; G M Winslow
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

6.  The type B leukemogenic virus truncated superantigen is dispensable for T-cell lymphomagenesis.

Authors:  Farah Mustafa; Sanchita Bhadra; Dennis Johnston; Mary Lozano; Jaquelin P Dudley
Journal:  J Virol       Date:  2003-03       Impact factor: 5.103

7.  A role for herpesvirus saimiri orf14 in transformation and persistent infection.

Authors:  M Duboise; J Guo; S Czajak; H Lee; R Veazey; R C Desrosiers; J U Jung
Journal:  J Virol       Date:  1998-08       Impact factor: 5.103

8.  Regions of mouse mammary tumor virus superantigen involved in interaction with the major histocompatibility complex class II I-A molecule.

Authors:  Susanne Wirth; Annelyse Vessaz; Claude Krummenacher; Frédéric Baribaud; Hans Acha-Orbea; Heidi Diggelmann
Journal:  J Virol       Date:  2002-11       Impact factor: 5.103

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.